Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1

Status

Unknown 3Recruiting 2Completed 2Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Nasopharyngeal Carcinoma 6Uterine Cervical Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Esophageal Squamous Cell Carcinoma 4Pancreatic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Stomach Neoplasms 2Nasopharyngeal Neoplasms 2Uterine Cervical Dysplasia 1Solid Tumors 1Solid Tumor 1Recurrence 1Oropharyngeal Neoplasms 1Neoplasms 1Nasopharyngeal Diseases 1NSCLC 1Meningeal Carcinomatosis 1Lung Neoplasms 1Locally Advanced Rectal Cancer 1Hypopharyngeal Neoplasms 1Head and Neck Neoplasms 1HCC 1Esophageal Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Childhood Brain Stem Neoplasm 1Carcinoma, Squamous Cell 1Breast Neoplasms 1Advanced Pancreatic Cancer 1Advanced Colorectal Cancer 1Advanced Cancer 1

Interventions

Gemcitabine 78Fluorouracil 27Oxaliplatin 24130-nm albumin-bound paclitaxel 24Leucovorin 18Capecitabine 15Albumin-Bound Paclitaxel 15S 1 (combination) 14Taxes 12Irinotecan 11pembrolizumab 9folfirinox 9Radiosurgery 9Radiotherapy 7Drug Therapy 7Cisplatin 7irinotecan sucrosofate 6Pancreaticoduodenectomy 5Paclitaxel 5Injections 5Docetaxel 5Blood Specimen Collection 5apatinib 4Radiofrequency Ablation 4Radiation 4Biopsy 4tislelizumab 3rubitecan 3nimotuzumab 3camrelizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × Pancreatic Neoplasms × nimotuzumab × Clear all
NCT06404840 2024-05-08

Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II Study

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
30 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT06405685 2024-05-08

Nimotuzumab Plus AG in Pancreatic Cancer With Liver Metastasis

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
30 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT02945267 2016-10-26

Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Unresectable Pancreatic Cancer

Chinese PLA General Hospital

Phase 4 Unknown
60 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡